(Q36742410)

16 August 2017

1 reference

title

Fibrates: what have we learned in the past 40 years? (English)

1 reference

16 August 2017

James M Backes

1

1 reference

16 August 2017

Cheryl A Gibson

series ordinal

2

1 reference

16 August 2017

Janelle F Ruisinger

series ordinal

3

1 reference

16 August 2017

Patrick M Moriarty

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

27

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

412-424

1 reference

Effect of different antilipidemic agents and diets on mortality: a systematic review

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Fibric acids: effects on lipids and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Role of C-reactive protein in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Effects of fenofibrate and gemfibrozil on plasma homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Statin safety and drug interactions: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Drug interactions with fibric acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Mechanistic studies on metabolic interactions between gemfibrozil and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Optimal lipid modification: the rationale for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Combination therapy in the management of complex dyslipidemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.412

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.3.412

1 reference

release_2ij3cwvtivgedf2emrkbw2ogq4

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2ij3cwvtivgedf2emrkbw2ogq4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference